Beijing Luzhu Clarifies Limits on Share Awards and Equity-Linked Deals in 2025 ReportTip Ranks·Sep 24, 2026 at 12:38 PM02480+1.32%
Asian Growth Stocks With High Insider OwnershipSimplywall·Sep 3, 2026 at 04:27 AM02480+1.32%301345+1.13%
Beijing Luzhu Biotechnology Publishes Unaudited Interim Results for First Half of 2026Tip Ranks·Aug 26, 2026 at 08:40 AM02480+1.32%
Beijing Luzhu Biotech FY26 H1 net loss narrows 20.6% to RMB 61.62 millionPUBT·Aug 26, 2026 at 08:31 AM02480+1.32%
Beijing Energy International schedules board meeting to review interim results, consider dividendPUBT·Aug 13, 2026 at 08:46 AM006860.00%
Luzhu Biotech’s Herpes Zoster Vaccine LZ901 Shows Strong Phase III Results in ChinaTip Ranks·Aug 9, 2026 at 10:37 AM02480+1.32%
Beijing Luzhu says Phase III trial shows LZ901 shingles vaccine efficacy at 91.6% in adults 40+PUBT·Aug 9, 2026 at 10:25 AM02480+1.32%
Luzhu Biotech narrowed its losses last year, with the shingles vaccine set to be launched soonBambooWorks·Mar 26, 2026 at 08:20 AM588860-1.53%516930-0.64%
"Performance" LUZHU BIOTECH-B's annual loss narrows to 150 million RMBAASTOCKS·Mar 18, 2026 at 03:16 PM5606000.00%513120-0.34%
LUZHU BIOTECH-B successfully completed Phase I clinical trial of LZ901 in the United StatesZhitong·Oct 9, 2025 at 11:08 AM02480+1.32%
LUZHU BIOTECH-B: Peng Ling has been appointed as the company's deputy general managerZhitong·Sep 25, 2025 at 09:17 AM02480+1.32%
As the core varieties approach the cash red line, when will LUZHU BIOTECH-B return to the market spotlight?Zhitong·Sep 11, 2025 at 09:11 AM02480+1.32%
"Performance" LUZHU BIOTECH's half-year loss narrowed to 77.57 million yuanAASTOCKS·Aug 26, 2025 at 08:31 AM02480+1.32%
Hong Kong pharmaceutical stocks strengthened, with Venus Medtech rising over 10%Zhitong·Aug 19, 2025 at 01:52 AM06628+2.38%01228-2.99%